Transforming life for patients with Parkinson’s disease

Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.

Two clinical phase II candidates

Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more >

Pirepemat (IRL752) in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more >

Proprietary technology platform

The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more >

Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease.

Read more here >

Latest press release

IRLAB obtains strengthened patent protection for Phase II candidate pirepemat

September 2, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) today announced that the company has been granted a new patent on the manufacturing process for the drug candidate pirepemat by the US Patent Office. Pirepemat is one of IRLAB’s clinical drug candidates and under development in Phase IIb for the treatment of impaired balance and falls in Parkinson’s disease.

Read More >
Latest presentation

Presention at ProHearings by Nicholas Waters, CEO (Swedish)

August 25, 2021 Read More >